647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma
- Resource Type
- Source
- Regular and Young Investigator Award Abstracts.
- Subject
- Language